Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.44 |
| ▸ | BACE1 | P56817 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700119 | 1.00 | ACHE (0.44) | ACHEBACE1KMT2ABCHEPOLB | |
| SCHEMBL23700118 | 1.00 | ACHE (0.44) | ACHEBACE1KMT2ABCHEPOLB | |
| SCHEMBL3597520 | 1.00 | ACHE (0.44) | ACHEBACE1KMT2ABCHEPOLB | |
| SCHEMBL2144440 | 0.95 | KMT2A (0.46) | ACHEBACE1KMT2ABCHEPOLB | |
| SCHEMBL2144437 | 0.95 | KMT2A (0.46) | ACHEBACE1KMT2ABCHEPOLB | |
| SCHEMBL19713578 | 0.95 | KMT2A (0.46) | ACHEBACE1KMT2ABCHEPOLB | |
| SCHEMBL19713577 | 0.95 | KMT2A (0.46) | ACHEBACE1KMT2ABCHEPOLB | |
| SCHEMBL3598418 | 0.90 | ACHE (0.46) | ACHEBACE1KMT2ABCHELMNA | |
| SCHEMBL3598416 | 0.90 | ACHE (0.46) | ACHEBACE1KMT2ABCHELMNA | |
| SCHEMBL29576208 | 0.84 | KMT2A (0.45) | ACHEBACE1KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110950840-B | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-110950840-A | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2020-04-03 | — | — | CN | claimed |
| US-11401269-B2 | Intermediates and processes for the preparation of Linagliptin and its salts | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2022-08-02 | — | — | US | disclosed |
| EP-3794001-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF LINAGLIPTIN AND ITS SALTS | CAMBREX PROFARMACO MILANO S R L (IT) | 2022-04-20 | — | — | EP | disclosed |
| CN-110950840-B | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-110950840-B | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20210238178-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF LINAGLIPTIN AND ITS SALTS | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2021-08-05 | — | — | US | disclosed |
| EP-3794001-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF LINAGLIPTIN AND ITS SALTS | Cambrex Profarmaco Milano S.r.l. (IT) | 2021-03-24 | — | — | EP | disclosed |
| CN-110950840-A | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| CN-101558057-B | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF | 2013-05-01 | — | — | CN | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| CN-101558057-A | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF (IT) | 2009-10-14 | — | — | CN | disclosed |
| EP-2099780-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008061688-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | ACHE 621/4885BACE1 1164/4885KMT2A 1204/4885 |
| US-11401269-B2 | Intermediates and processes for the preparation of Linagliptin and its salts | DPP4, DPP8, DPP9 | ACHE 1579/4885BACE1 970/4885KMT2A 3121/4885 |
| US-20210238178-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF LINAGLIPTIN AND ITS SALTS | DPP4, DPP8, DPP9 | ACHE 1579/4885BACE1 970/4885KMT2A 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.